iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
54 hedge funds and large institutions have $614M invested in iTeos Therapeutics in 2020 Q3 according to their latest regulatory filings, with 54 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
71.2% more ownership
Funds ownership: 0% → 71.2% (+71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$119M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$117M |
| 3 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$99.7M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$63.4M |
| 5 |
AG
Artal Group
Luxembourg
|
+$29.4M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Legal & General Group
London,
United Kingdom
| $29K | +$32.1K | +1,193 | New |
|
|
AIP
52
Ameritas Investment Partners
Lincoln,
Nebraska
| $22K | +$24.5K | +911 | New |
|
53
Citigroup
New York
| $13K | +$13.8K | +513 | New |
|
54
Bank of Montreal
Toronto,
Ontario, Canada
| $11K | +$13.3K | +496 | New |
|
ITOS Hedge Fund Activity: Q3 2020 in Review
54 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2020, worth a combined $614M.
Buyers outnumbered sellers: 54 funds opened new ITOS positions and 0 closed out — a net gain of 54 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $119M.
- 54 institutional investors held iTeos Therapeutics (ITOS) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $614M of iTeos Therapeutics stock for Q3 2020.
- 54 funds opened new iTeos Therapeutics positions in Q3 2020 and 0 closed out, a net change of +54 holders.
- The largest iTeos Therapeutics buyer in Q3 2020 was RA Capital Management, an estimated $119M added.
Based on aggregated 13F filings for Q3 2020.